WO2007041156A3 - Antibiotic formulations, unit doses, kits, and methods - Google Patents

Antibiotic formulations, unit doses, kits, and methods Download PDF

Info

Publication number
WO2007041156A3
WO2007041156A3 PCT/US2006/037651 US2006037651W WO2007041156A3 WO 2007041156 A3 WO2007041156 A3 WO 2007041156A3 US 2006037651 W US2006037651 W US 2006037651W WO 2007041156 A3 WO2007041156 A3 WO 2007041156A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
methods
unit doses
gram
salt
Prior art date
Application number
PCT/US2006/037651
Other languages
French (fr)
Other versions
WO2007041156A2 (en
Inventor
Chatan K Charan
Dwivedi Sarvajna
Original Assignee
Nektar Therapeutics
Chatan K Charan
Dwivedi Sarvajna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics, Chatan K Charan, Dwivedi Sarvajna filed Critical Nektar Therapeutics
Priority to BRPI0616642-3A priority Critical patent/BRPI0616642A2/en
Priority to US11/992,347 priority patent/US9205050B2/en
Priority to JP2008533562A priority patent/JP2009510077A/en
Priority to AU2006297289A priority patent/AU2006297289B2/en
Priority to CA002622193A priority patent/CA2622193A1/en
Priority to MX2013004748A priority patent/MX348936B/en
Priority to EP06815563A priority patent/EP1928410A2/en
Priority to KR1020087007893A priority patent/KR101424518B1/en
Publication of WO2007041156A2 publication Critical patent/WO2007041156A2/en
Publication of WO2007041156A3 publication Critical patent/WO2007041156A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/065—Rigid ampoules, e.g. glass ampoules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Abstract

An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25°C and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.
PCT/US2006/037651 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods WO2007041156A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0616642-3A BRPI0616642A2 (en) 2005-09-29 2006-09-28 antibiotic formulations, unit doses, kits and methods
US11/992,347 US9205050B2 (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits and methods
JP2008533562A JP2009510077A (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits and methods
AU2006297289A AU2006297289B2 (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods
CA002622193A CA2622193A1 (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods
MX2013004748A MX348936B (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods.
EP06815563A EP1928410A2 (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods
KR1020087007893A KR101424518B1 (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72256405P 2005-09-29 2005-09-29
US60/722,564 2005-09-29

Publications (2)

Publication Number Publication Date
WO2007041156A2 WO2007041156A2 (en) 2007-04-12
WO2007041156A3 true WO2007041156A3 (en) 2008-03-06

Family

ID=37744353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037651 WO2007041156A2 (en) 2005-09-29 2006-09-28 Antibiotic formulations, unit doses, kits, and methods

Country Status (10)

Country Link
US (6) US20070116649A1 (en)
EP (1) EP1928410A2 (en)
JP (1) JP2009510077A (en)
KR (1) KR101424518B1 (en)
CN (2) CN104586868A (en)
AU (1) AU2006297289B2 (en)
BR (1) BRPI0616642A2 (en)
CA (1) CA2622193A1 (en)
MX (1) MX348936B (en)
WO (1) WO2007041156A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
JP5064383B2 (en) 2005-05-25 2012-10-31 エアロジェン，インコーポレイテッド Vibration system and method
EP1928410A2 (en) 2005-09-29 2008-06-11 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
DE102006004528A1 (en) * 2006-02-01 2007-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Artificial breathing device for supplying respiratory gas links to a powder inhalator for inhalative administration of medication to patients connected to respiratory equipment
KR20100060004A (en) * 2007-09-25 2010-06-04 노파르티스 아게 Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009064469A1 (en) * 2007-11-14 2009-05-22 Nektar Therapeutics Pulmonary delivery of a macrolide antibiotic
US9016275B2 (en) * 2007-12-19 2015-04-28 Neores Ab Nebulising device for use in a CPAP-system
US8418690B2 (en) * 2008-09-26 2013-04-16 Stamford Devices Limited Supplemental oxygen delivery system
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
CN102573967B (en) 2009-07-17 2014-06-11 内克塔医疗公司 Negatively biased sealed nebulizers systems and methods
CN101797379A (en) * 2010-03-15 2010-08-11 甘能金 Combination humidifying liquor for ultrasonic atomization therapy
KR101272351B1 (en) 2010-04-23 2013-06-07 이화여자대학교 산학협력단 New kanamycin compound, kanamycin-producing Streptomyces sp. and kanamycin producing method
US8598131B2 (en) * 2010-07-12 2013-12-03 Xellia Pharmaceuticals Aps Method for treatment of lung infections by administration of aminoglycosides by aerolisation
ITLO20110001A1 (en) * 2011-05-03 2012-11-04 Fisiopharma Srl VANCOMICINA CHLOROIDRATE BOTTLES WITH IMPROVED STABILITY
CN103732213A (en) 2011-06-07 2014-04-16 帕里昂科学公司 Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
KR20140025534A (en) 2011-07-12 2014-03-04 카르데아스 파마 인코퍼레이티드 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia(vap) and ventilator associated tracheal(vat) bronchitis
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
US8746241B2 (en) 2011-10-03 2014-06-10 Sabrina B. Cavendish Combination MDI and nebulizer adapter for a ventilator system
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
WO2013181459A1 (en) * 2012-05-30 2013-12-05 The University Of Kansas Inhalation device, systems, and methods for administering powdered medicaments to mechanically ventilated subjects
WO2014052799A1 (en) * 2012-09-27 2014-04-03 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
BR112015015789A2 (en) * 2013-01-04 2017-07-11 Gea Food Solutions Bakel Bv line and process for drying and cooking a food product
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
PE20160048A1 (en) * 2013-03-15 2016-02-12 Merck Sharp & Dohme ANTIBIOTIC COMPOSITIONS OF CEFTOLOZANE
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) * 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US20160250142A1 (en) * 2013-10-30 2016-09-01 Inspirx Llc Inhaled aerosolized immuno-chemotherapy for the treatement of mdr tb
USD747701S1 (en) * 2014-06-10 2016-01-19 Brian Janezic Drum transponder
WO2016004321A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Compounds for treating biofilm infection
USD747294S1 (en) * 2014-10-14 2016-01-12 Brian Janezic Modified drum transponder
EP3253391B1 (en) 2015-02-06 2021-09-08 Latitude Pharmaceuticals Incorporated Aqueous solution formulations of vancomycin
CN110339341A (en) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 A kind of composition of Daptomycin or its salt
EP3843819A1 (en) * 2018-12-06 2021-07-07 Stamford Devices Limited Aerosolised medication of ventilated patients with minimised dead volume
CN111714496A (en) * 2019-03-18 2020-09-29 深圳市益米诺医药科技有限公司 Application of small molecular compound in improving host pathogenic bacteria removing capability and application in preparing anti-pathogenic bacteria infection medicine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6387886B1 (en) * 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
US20040035413A1 (en) * 2002-05-07 2004-02-26 The Research Foundation Methods, devices and formulations for targeted endobronchial therapy
US20040131555A1 (en) * 2001-05-18 2004-07-08 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
WO2004110346A2 (en) * 2002-10-29 2004-12-23 Transave, Inc. Sustained release of antiinfectives
WO2005037256A2 (en) * 2003-10-15 2005-04-28 Pari Gmbh Liquid preparation containing tobramycin

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL53427A0 (en) * 1976-11-24 1978-01-31 Lilly Co Eli Method of preparing a rapidly dissolving powder of sterile crystalline cefozolin sodium for parenteral administration
US4684643A (en) * 1983-08-22 1987-08-04 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5373095A (en) * 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
IT1225484B (en) * 1987-11-27 1990-11-14 Pierrel Spa SYNTHESIS PROCEDURE OF AMIKACINA
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5562608A (en) * 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Aerosol propellant compositions
EP0446670B1 (en) * 1990-03-08 1994-09-21 Biochimica Opos Spa Method of preparation of amikacin precursors
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
PT98105B (en) 1990-06-28 1998-11-30 Glaxo Inc PROCESS FOR THE PREPARATION OF FORMULATIONS IN AEROSOL CONTAINING AS PROPULSOR 1,1,1,2-TETRAFLUOROETHANE
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
DK0656207T4 (en) * 1991-06-10 2009-11-30 Schering Corp Aerosol formulations without chlorofluorocarbon compounds
FI90926C (en) 1992-05-14 1994-04-11 Lk Products Oy High frequency filter with switching property
US5840277A (en) * 1993-03-30 1998-11-24 Charlotte Hospital Authority Treatment of chronic pulmonary inflammation
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5655520A (en) 1993-08-23 1997-08-12 Howe; Harvey James Flexible valve for administering constant flow rates of medicine from a nebulizer
CA2178473C (en) 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5663152A (en) * 1995-01-19 1997-09-02 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators for aminoglycosides
AUPN771596A0 (en) * 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
US6858589B2 (en) * 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001004752A2 (en) 1999-07-13 2001-01-18 Robert Coates A method and system of allowing prospective users to test and use software via a computer network
US7742972B2 (en) * 1999-07-21 2010-06-22 Longitude Llc Enhanced parimutuel wagering
WO2001047542A1 (en) * 1999-12-28 2001-07-05 Meiji Seika Kaisha, Ltd. Vancomycin preparations
US6596261B1 (en) * 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US6410533B1 (en) * 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
MXPA02010884A (en) 2000-05-05 2003-03-27 Aerogen Ireland Ltd Apparatus and methods for the delivery of medicaments to the respiratory system.
US8336545B2 (en) * 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
EP1328214A4 (en) * 2000-09-20 2009-07-29 Shahinian Lee Jr Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6565873B1 (en) * 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
AU2002246567A1 (en) * 2000-11-01 2002-07-30 Wayne State University Aminoglycosides as antibiotics
US20020134373A1 (en) * 2001-03-20 2002-09-26 Igor Gonda Aerosol generation using sterile multiple dose containers
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20030133925A1 (en) 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
ES2603067T3 (en) * 2002-01-15 2017-02-23 Novartis Ag Methods and systems for operating an aerosol generator
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
WO2004071368A2 (en) 2002-05-07 2004-08-26 The State University Of New York At Stony Brook Methods, devices and formulations for targeted endobronchial therapy
ITMI20022299A1 (en) * 2002-10-29 2004-04-30 St Microelectronics Srl DEVICE FOR PILOTING A POWER TRANSITOR
WO2004052333A1 (en) 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
DE10347994A1 (en) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Aqueous aerosol preparation
AU2004291172B2 (en) * 2003-11-17 2010-11-11 Novartis Ag Efficient introduction of an aerosol into a ventilator circuit
US7290541B2 (en) * 2004-04-20 2007-11-06 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
US7267121B2 (en) * 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
CN1976703A (en) 2004-06-30 2007-06-06 诺瓦提斯公司 Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors
WO2006055950A1 (en) 2004-11-18 2006-05-26 Nektar Therapeutics Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents
KR20080011392A (en) * 2005-05-19 2008-02-04 파커-한니핀 코포레이션 Thermal lamination module
EP1928410A2 (en) * 2005-09-29 2008-06-11 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
WO2007124382A2 (en) 2006-04-19 2007-11-01 Novartis Vaccines And Diagnostics, Inc. Inhaled imipenem
KR20100060004A (en) 2007-09-25 2010-06-04 노파르티스 아게 Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
WO2009120619A2 (en) 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
KR20140025534A (en) * 2011-07-12 2014-03-04 카르데아스 파마 인코퍼레이티드 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia(vap) and ventilator associated tracheal(vat) bronchitis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6387886B1 (en) * 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
US20040131555A1 (en) * 2001-05-18 2004-07-08 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20040035413A1 (en) * 2002-05-07 2004-02-26 The Research Foundation Methods, devices and formulations for targeted endobronchial therapy
WO2004110346A2 (en) * 2002-10-29 2004-12-23 Transave, Inc. Sustained release of antiinfectives
WO2005037256A2 (en) * 2003-10-15 2005-04-28 Pari Gmbh Liquid preparation containing tobramycin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1991, GOOCH M D: "Stability of albuterol and tobramycin when mixed for aerosol administration", XP002445579, Database accession no. EMB-1992054364 *
RESPIRATORY CARE 1991 UNITED STATES, vol. 36, no. 12, 1991, pages 1387 - 1390, ISSN: 0098-9142 *

Also Published As

Publication number Publication date
CA2622193A1 (en) 2007-04-12
AU2006297289B2 (en) 2013-03-21
CN101287446A (en) 2008-10-15
US20090288658A1 (en) 2009-11-26
MX348936B (en) 2017-07-03
WO2007041156A2 (en) 2007-04-12
US9351929B2 (en) 2016-05-31
US20100286031A1 (en) 2010-11-11
US9895386B2 (en) 2018-02-20
US20120225835A1 (en) 2012-09-06
US20070116649A1 (en) 2007-05-24
BRPI0616642A2 (en) 2011-06-28
US20120247462A1 (en) 2012-10-04
AU2006297289A1 (en) 2007-04-12
KR20080049808A (en) 2008-06-04
US20160317562A1 (en) 2016-11-03
JP2009510077A (en) 2009-03-12
US9351930B2 (en) 2016-05-31
US9205050B2 (en) 2015-12-08
EP1928410A2 (en) 2008-06-11
KR101424518B1 (en) 2014-08-06
CN104586868A (en) 2015-05-06

Similar Documents

Publication Publication Date Title
WO2007041156A3 (en) Antibiotic formulations, unit doses, kits, and methods
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
TW200744588A (en) Pharmaceutical composition for external use
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
UA94065C2 (en) Dihydropseudoerythromycin derivatives
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
WO2008143240A1 (en) Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2006086562A3 (en) Phenylazetidinone derivatives
HK1131518A1 (en) Ornithine conjugates of amphetamine and processes for making and using the same
TW200716202A (en) Pediatric formulation of topiramate
WO2007022956A3 (en) Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
WO2006120563A3 (en) Antibacterial agents
UA97346C2 (en) Stable emulsion composition
WO2007016352A3 (en) Oral liquid losartan compositions
MX2008001560A (en) Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds.
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2007058568A3 (en) Salts of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols
WO2008073863A3 (en) Preparation and utility of substituted allylamines
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
SI2142174T1 (en) Stable aqueous g-csf formulations
TW200724145A (en) Substituted acrylamide derivatives and pharmaceutical compositions thereof
MX2010009244A (en) Amide derivative and pharmaceutical composition containing the same.
GEP20125525B (en) Stable liquid pharmaceutical composition based on trazodone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680036148.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2622193

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006297289

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006815563

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008533562

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004378

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087007893

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006297289

Country of ref document: AU

Date of ref document: 20060928

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11992347

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0616642

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080331